Cyclo Therapeutics Inc - Ordinary Shares - Class A
NASDAQ:CYTH
| Market Cap (Intraday) | 44.04M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $5.78 |
| 50-Day MA | $6.51 |
| 200-Day MA | $7.99 |
Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock, NASDAQ:CYTH
6714 NW 16th Street, Suite B, Gainesville, Florida 32653
United States of America
Phone: +1.386.418.8060
Number of Employees: 8
Description
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.